CRISPR rises after FDA accepts review of first ever gene editing therapy

Crispr Therapeutics AG

09/06/2023 12:43

** U.S.-listed shares of Swiss-based gene editing company
CRISPR Therapeutics AG  CRSP.O  up 5.1% at $65.8 premarket
    ** U.S. FDA late-Thursday accepted review of marketing
application for CRSP's experimental gene-editing therapy,
exa-cel, for two types of blood disorders - co 
    ** CRSP is developing exa-cel with partner Vertex
Pharmaceuticals Inc  VRTX.O  as a potential one-time treatment,
which would be the first therapy to use the nobel-winning CRISPR
gene editing technology if approved 
    ** FDA has granted priority review for the therapy in severe
sickle cell disease (SCD) and a standard review for
transfusion-dependent beta thalassemia (TDT)
    ** FDA is set to make a decision on the therapy's use in SCD
and TDT by December 8, 2023, and March 30, 2024, respectively -
co
    ** Separately on Friday, CRSP/VRTX reported updated data on
the therapy and said it met primary and key secondary study
goals at interim analyses of the trials
    ** Up to Thursday close, stock gained nearly 54% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))